Lilly Announces Positive Results for Two Phase 3 Studies of Taltz
October 22 2018 - 5:12PM
Dow Jones News
By Stephen Nakrosis
Eli Lilly and Co. (LLY) on Monday said the company will announce
positive results from two Phase 3 studies in adults with ankylosing
spondylitis.
The analyses are part of a clinical development program that
aims to evaluate Taltz across various populations of patients with
ankylosing spondylitis, the company said.
Ankylosing spondylitis is an inflammatory disease that can cause
vertebrae in the spine to fuse.
The company said COAST-V was the first successful ankylosing
spondylitis trial to use ASAS40 as the primary endpoint, and
COAST-W is the first ankylosing spondylitis trial to specifically
focus on patients who had failed one or two tumor necrosis factor
inhibitors or are intolerant to such an inhibitor. COAST-W also was
able to generate data on spinal MRI inflammation in this patient
population.
Taltz also demonstrated a statistically significant improvement
on several secondary endpoints.
Eli Lilly will present findings at the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Meeting in Chicago on October 23.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 22, 2018 16:57 ET (20:57 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024
